LITHA HEALTHCARE GROUP LIMITED - Litha announces change in majority shareholder

Litha announces change in majority shareholder

LITHA HEALTHCARE GROUP LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2006/006371/06);
Share code: LHG, ISIN: ZAE000144671
(“Litha”)



LITHA ANNOUNCES CHANGE IN MAJORITY SHAREHOLDER

Litha announces that its majority shareholder, Paladin Labs Inc. (TSX:PLB) (“Paladin”) has reached a
definitive agreement to be acquired by Endo Health Solutions (NASDAQ:ENDP) (“Endo”), a leading
U.S.-based specialty pharmaceutical company.
Paladin currently holds a majority shareholding in Litha having recently increased its holding in the
company.

The stock and cash transaction is valued at approximately US$1.7 billion and will be acquired by a
newly-formed Irish holding company (“New Endo”). Paladin will remain in Montreal, led by the current
management team and will trade under the name of Paladin Labs, as a subsidiary of the new holding
company.

Litha does not expect any operational impact to their current business.

Endo Health Solutions Inc. is a U.S.-based specialty healthcare company with four distinct business
segments that are focused on branded and generic pharmaceuticals, devices and services, each
providing quality products to our customers while improving the lives of patients. Through its operating
companies - AMS, Endo Pharmaceuticals, HealthTronics and Qualitest - Endo is dedicated to finding
solutions for the unmet needs of patients. Learn more at www.endo.com.

Sponsor

Rand Merchant Bank (a division of FirstRand Bank Limited)

Midrand

6 November 2013

Date: 06/11/2013 04:34:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.